Kogenate Fs (Bayer, 250 Unit, 500 Unit, 1000 Unit): Uses, Side Effects and Dosage

ABOUT THIS MEDICATION

What the medication is used for:

KOGENATE FS (Antihemophilic Factor [Recombinant]) is used for the treatment of hemophilia A. Patients who have hemophilia A do not have enough clotting Factor VIII, which helps control bleeding. KOGENATE FS can be used to prevent bleeding before it happens, or it can be used to stop a bleeding episode that has already begun in patients who have hemophilia A.

When used as a regular prophylactic treatment, KOGENATE FS is also indicated to prevent the occurrence of spontaneous hemorrhagic episodes and to prevent joint damage in children with.

What it does:

KOGENATE FS is clotting Factor VIII that has been developed in the laboratory. It is very similar to the Factor VIII that occurs naturally in human blood. In patients with hemophilia A, who do not have enough natural Factor VIII in their blood, KOGENATE FS gives them additional Factor VIII to help prevent and/or control bleeding. KOGENATE FS is given directly into the blood through an injection in a vein.

When it should not be used:

KOGENATE FS does not contain von Willebrand Factor and therefore, is not indicated for the treatment of von Willebrand disease.

What the medicinal ingredient is:

Antihemophilic Factor (Recombinant)

What the nonmedicinal ingredients are:

• Sucrose
• Glycine
• Histidine
• Calcium chloride
• Sodium
• Chloride
• Polysorbate 80

KOGENATE FS does not contain any preservatives. What dosage forms it comes in:

KOGENATE FS is a dried product powder available in vials containing 250 IU*, 500 IU, 1000 IU, (with 2.5 mL Sterile Water for Injection), and 2000 IU (with 5.0 mL Sterile Water for Injection) and supplied with an administration set. After reconstitution, KOGENATE FS is given by direct injection into a vein, usually over 5 to 10 minutes. You may also receive treatment presurgery by an initial bolus (all at once) injection followed immediately by continuous infusion.

* IU = International Units

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Some people can develop inhibitors to treatment with Factor VIII.

Inhibitors to treatment with Factor VIII are antibodies that can reduce the effectiveness of treatment. Anyone can develop inhibitors, but they are especially common in young children with severe hemophilia during their first years of treatment and any patient who has had little previous treatment with Factor VIII. Your hemophilia healthcare team will monitor you carefully for the development of inhibitors.

Be careful when handling the administration set and needle, to minimize the possibility of accidental needlestick injuries. Contact your healthcare team immediately if you accidentally injure yourself.

Rarely, some people have allergic reactions to Factor VIII. If you develop low blood pressure, a rash, hives, wheezing or tightness in your chest, seek immediate emergency treatment.

BEFORE you use KOGENATE FS talk to your doctor or pharmacist if

• you are allergic to mouse or hamster protein, or any of the ingredients in KOGENATE FS.
• you have had inhibitor development in the past.

• you are pregnant, are trying to become pregnant or are a nursing mother.

INTERACTIONS WITH THIS MEDICATION

None known.

See also ABOUT THIS MEDICATION: When it should not be used, and SIDE EFFECTS AND WHAT TO DO ABOUT THEM.

PROPER USE OF THIS MEDICATION

Usual dose

Your doctor will calculate the best dosage for you, based on your weight, blood tests of your Factor VIII level, and whether KOGENATE FS is being used to prevent or stop a bleeding episode. You and your healthcare team will work together to find out what dosage and schedule works best for you.

General guidelines for dosage:

• A minor bleeding episode will be treated with 10-20 IU

  for every kilogram of body weight.

• A moderate/major bleeding episode will be treated with

  15-30 IU for every kilogram of body weight.

• A major/very serious bleeding episode will be treated

  with 40-50 IU for every kilogram of body weight.

• Surgical procedures may require 50 IU for every kilogram

  of body weight before the operation. You may also receive treatment presurgery by an initial bolus (all at once) injection followed immediately by continuous infusion.

• Patients who have inhibitors may require higher dosages.

• The regular prophylaxis schedule for children is 25 IU/kg

  of body weight every other day.

Overdose

No symptoms of overdose have been reported.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

In patients who have had previous treatment with Factor VIII, some side effects included reactions at the injection site, rash, and itchy skin.

In patients who had no previous treatment with Factor VIII, some side effects included formation of inhibitors to Factor VIII, reactions at the injection site, rash, and itchy skin.

You may find that more KOGENATE FS is required than estimated to stop the bleeding (lack of effect).

If you are concerned about any possible side effects, talk to your doctor.

This is not a complete list of side effects. For any unexpected effects while taking KOGENATE FS, contact your doctor or pharmacist.

HOW TO STORE IT

Keep KOGENATE FS in the refrigerator (2°C-8°C). You may store the powder at room temperature (up to 25°C) for 3 months. If the KOGENATE FS is stored outside the refrigerator, please add the date removed from refrigeration and note a new expiry date on the carton and vial. The next expiry date is 3 months from the date product is removed from the refrigerator, or the previously stamped expiry date, whichever is shorter. Once KOGENATE FS has been removed from refrigeration, it cannot be returned to the refrigerator. Store away from extreme light and do not use after the expiration date on the bottle. Do not freeze. Store the powder in the carton.

REPORTING SUSPECTED SIDE EFFECTS

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be obtained by contacting the sponsor, Bayer Inc., at: 1-800-265-7382

Bayer Inc.

77 Belfield Road

Toronto, Ontario M9W 1G6

Canada

Last revised: July 7, 2009

© 2009, Bayer Inc.

® KOGENATE, Bayer and Bayer Cross are registered trademarks of Bayer AG, used under license by Bayer Inc.